ES2106195T3 - Anticuerpo igg aglicosilado anti cd3. - Google Patents

Anticuerpo igg aglicosilado anti cd3.

Info

Publication number
ES2106195T3
ES2106195T3 ES92921508T ES92921508T ES2106195T3 ES 2106195 T3 ES2106195 T3 ES 2106195T3 ES 92921508 T ES92921508 T ES 92921508T ES 92921508 T ES92921508 T ES 92921508T ES 2106195 T3 ES2106195 T3 ES 2106195T3
Authority
ES
Spain
Prior art keywords
aglycosilated
igg
antibody anti
antibody
immunosuppression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92921508T
Other languages
English (en)
Spanish (es)
Inventor
Sarah Louise Bolt
Michael Ronald Clark
Scott David Gorman
Edward Graham Routledge
Herman Waldmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
British Technology Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Technology Group Ltd filed Critical British Technology Group Ltd
Application granted granted Critical
Publication of ES2106195T3 publication Critical patent/ES2106195T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES92921508T 1992-03-24 1992-10-21 Anticuerpo igg aglicosilado anti cd3. Expired - Lifetime ES2106195T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929206422A GB9206422D0 (en) 1992-03-24 1992-03-24 Antibody preparation

Publications (1)

Publication Number Publication Date
ES2106195T3 true ES2106195T3 (es) 1997-11-01

Family

ID=10712757

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92921508T Expired - Lifetime ES2106195T3 (es) 1992-03-24 1992-10-21 Anticuerpo igg aglicosilado anti cd3.

Country Status (12)

Country Link
US (11) US5585097A (OSRAM)
EP (1) EP0586617B1 (OSRAM)
JP (3) JP4065554B2 (OSRAM)
KR (1) KR100238497B1 (OSRAM)
AT (1) ATE155818T1 (OSRAM)
AU (1) AU671085B2 (OSRAM)
CA (1) CA2109815C (OSRAM)
DE (1) DE69221147T2 (OSRAM)
ES (1) ES2106195T3 (OSRAM)
GB (1) GB9206422D0 (OSRAM)
GR (1) GR3024489T3 (OSRAM)
WO (1) WO1993019196A1 (OSRAM)

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
ATE248192T1 (de) * 1996-06-07 2003-09-15 Neorx Corp HUMANISIERTE ANTIKÖRPER DIE AN DAS GLEICHE ANTIGEN WIE ANTIKÖRPER NR-LU-13 BINDEN UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CN1763097B (zh) * 1999-01-15 2011-04-13 杰南技术公司 具有改变的效应功能的多肽变体
EP1228214A2 (en) * 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
ES2312494T3 (es) * 2000-12-14 2009-03-01 Genentech, Inc. Produccion de anticuerpos completos en celulas procariotas.
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US6720165B2 (en) 2001-06-14 2004-04-13 Zyomix, Inc. Methods for making antibody fragments and compositions resulting therefrom
JP4461210B2 (ja) * 2001-08-27 2010-05-12 ジェネンテック， インコーポレイテッド 抗体発現系とその構築法
GB2380127A (en) 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
DK1443961T3 (da) * 2001-10-25 2009-08-24 Genentech Inc Glycoprotein-sammensætninger
US20050129691A1 (en) * 2002-04-25 2005-06-16 Eli Lily And Company Patent Division Method for treating anxiety and mood disorders in older subjects
NZ538996A (en) * 2002-10-31 2008-04-30 Genentech Inc Methods and compositions for increasing antibody production
WO2005003175A2 (en) * 2003-06-13 2005-01-13 Biogen Idec Ma Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
JP2007503206A (ja) * 2003-08-22 2007-02-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 変更されたエフェクター機能を有する改良された抗体およびその抗体を産生する方法
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US20050152894A1 (en) * 2003-09-05 2005-07-14 Genentech, Inc. Antibodies with altered effector functions
KR100775343B1 (ko) 2003-11-13 2007-11-08 한미약품 주식회사 면역글로불린 Ｆｃ 영역을 캐리어로 포함하는 약제학적조성물
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
AU2004309050B2 (en) * 2003-12-30 2010-10-14 Merck Patent Gmbh IL-7 fusion proteins
CA2551916C (en) 2003-12-31 2014-04-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
WO2006033702A2 (en) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies
MX2007002856A (es) * 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
NZ556788A (en) 2005-01-05 2011-03-31 Biogen Idec Inc Humanized CRIPTO binding molecules with CDRs from murine B3F6
US7812135B2 (en) 2005-03-25 2010-10-12 Tolerrx, Inc. GITR-binding antibodies
US8901281B2 (en) * 2005-06-17 2014-12-02 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
SG163615A1 (en) 2005-07-11 2010-08-30 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
JP5846712B2 (ja) * 2005-08-16 2016-01-20 ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅｃｏ．，Ｌｔｄ． 開始メチオニン残基が除去された免疫グロブリンＦｃ領域の大量生産方法
AR057807A1 (es) * 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
DK1966238T3 (da) * 2005-12-30 2012-07-16 Merck Patent Gmbh INTERLEUKIN-12P40-varianter med forbedret stabilitet
PT2270050E (pt) 2005-12-30 2013-09-12 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
EP2433650A3 (en) 2006-06-06 2012-12-19 Tolerrx Inc. Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
CA2655080A1 (en) * 2006-06-14 2007-12-21 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
JP5597793B2 (ja) * 2006-06-19 2014-10-01 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｌｔ３結合分子およびその使用
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation
US20100325744A1 (en) * 2007-05-31 2010-12-23 Genmab A/S Non-glycosylated recombinant monovalent antibodies
AU2008275589B2 (en) * 2007-07-12 2013-11-21 Gitr, Inc. Combination therapies employing GITR binding molecules
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2598530A2 (en) 2010-07-29 2013-06-05 Xencor, Inc. Antibodies with modified isoelectric points
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
AU2011337697B2 (en) 2010-11-30 2016-10-27 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US9249217B2 (en) 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
CN103619876A (zh) 2011-03-10 2014-03-05 Hco抗体股份有限公司 双特异性三链抗体样分子
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
EA033677B1 (ru) 2011-05-21 2019-11-15 Macrogenics Inc Cd3-связывающие молекулы, способные к связыванию с cd3 человека и cd3, не являющимся человеческим
EP3939613A1 (en) 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
MX359775B (es) 2011-10-31 2018-10-10 Chugai Pharmaceutical Co Ltd Molecula enlazada al antigeno que tiene conjugacion regulada entre cadena ligera y cadena pesada.
RS62509B1 (sr) 2012-07-13 2021-11-30 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti
WO2014028939A2 (en) 2012-08-17 2014-02-20 California Institute Of Technology Targeting phosphofructokinase and its glycosylation form for cancer
AU2013308409A1 (en) 2012-08-31 2015-03-26 University Of Birmingham Target peptides for immunotherapy and diagnostics
US10682399B2 (en) 2012-09-05 2020-06-16 The University Of Birmingham Target peptides for colorectal cancer therapy and diagnostics
US20160000893A1 (en) 2012-12-13 2016-01-07 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
WO2014110601A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
JP2016093104A (ja) * 2013-02-19 2016-05-26 国立大学法人京都大学 抗ヒトＣＤ３ε抗体又はそのフラグメント、及びそれを有効成分とする免疫抑制剤
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
CA2906927C (en) 2013-03-15 2021-07-13 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
KR101895634B1 (ko) 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
PL3122781T3 (pl) 2014-03-28 2020-06-15 Xencor, Inc. Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
SG11201607434WA (en) 2014-04-07 2016-10-28 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
AU2015247727A1 (en) 2014-04-15 2016-11-03 University Of Virginia Patent Foundation Isolated T cell receptors and methods of use therefor
KR20170017916A (ko) 2014-05-13 2017-02-15 추가이 세이야쿠 가부시키가이샤 면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자
PL3148579T3 (pl) 2014-05-28 2021-07-19 Agenus Inc. Przeciwciała anty-gitr i sposoby ich zastosowania
BR112017001579A2 (pt) 2014-07-25 2017-11-21 Cytomx Therapeutics Inc anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
HRP20211273T1 (hr) 2014-11-26 2021-11-12 Xencor, Inc. Heterodimerna protutijela koja vežu cd3 i cd20
TN2017000222A1 (en) 2014-11-26 2018-10-19 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
GB2557389B (en) 2015-01-14 2020-12-23 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
BR112017023849A2 (pt) 2015-05-07 2018-07-17 Agenus Inc. anticorpos anti-ox40 e métodos de uso dos mesmos
EP3091032A1 (en) 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3
MA45352A (fr) 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
CN107949573B (zh) 2015-09-01 2022-05-03 艾吉纳斯公司 抗-pd-1抗体及其使用方法
GB201520191D0 (en) 2015-11-16 2015-12-30 Cancer Rec Tech Ltd T-cell receptor and uses thereof
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
MX2018006477A (es) 2015-12-02 2018-09-03 Agenus Inc Anticuerpos y metodos de uso de estos.
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
AU2017233658B2 (en) 2016-03-14 2023-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
HRP20241447T1 (hr) 2016-06-14 2025-01-03 Xencor, Inc. Bispecifična inhibitor antitijela kontrolnih točaka
KR102531889B1 (ko) 2016-06-20 2023-05-17 키맵 리미티드 항-pd-l1 및 il-2 사이토카인
US11613572B2 (en) 2016-06-21 2023-03-28 Teneobio, Inc. CD3 binding antibodies
CN116063545A (zh) 2016-06-28 2023-05-05 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
IL313895A (en) 2016-09-14 2024-08-01 Teneoone Inc CD3 binding antibodies
AU2017343621B2 (en) 2016-10-11 2021-12-02 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
KR102562519B1 (ko) 2016-10-14 2023-08-02 젠코어 인코포레이티드 IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
JP2020508436A (ja) 2016-12-07 2020-03-19 プロジェニティ， インコーポレイテッド 胃腸管の検出方法、装置およびシステム
AU2017373944B2 (en) 2016-12-07 2022-02-03 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
KR20240017409A (ko) 2017-04-13 2024-02-07 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
KR20250007003A (ko) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
CN118146370A (zh) 2017-06-20 2024-06-07 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
EP3645560B1 (en) 2017-06-30 2023-12-20 Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) Treatment of haematological malignancies
TN2020000015A1 (en) 2017-08-03 2021-10-04 Amgen Inc Interleukin-21 muteins and methods of treatment
TWI870011B (zh) 2017-08-25 2025-01-11 美商戊瑞治療有限公司 Ｂ７－ｈ４抗體及其使用方法
EP4403175A3 (en) 2017-09-08 2024-10-02 Amgen Inc. Inhibitors of kras g12c and methods of using the same
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
CN111886250A (zh) 2017-12-27 2020-11-03 特尼奥生物股份有限公司 CD3-δ/ε异二聚体特异性抗体
SG11202005605SA (en) 2018-01-12 2020-07-29 Amgen Inc Anti-pd-1 antibodies and methods of treatment
TWI890481B (zh) 2018-02-09 2025-07-11 日商小野藥品工業股份有限公司 雙特異性抗體
MA51903A (fr) 2018-02-21 2021-05-26 Five Prime Therapeutics Inc Formulations d'anticorps b7-h4
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
MX2020010910A (es) 2018-04-18 2021-02-09 Xencor Inc Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
WO2019231326A1 (en) 2018-05-31 2019-12-05 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n.LUMC) Teipp neoantigens and uses thereof
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
TW202019477A (zh) 2018-07-31 2020-06-01 德商安美基研究（慕尼黑）公司 BCMAxCD3抗體構建體之給藥方案
SG11202100987RA (en) 2018-08-03 2021-02-25 Amgen Res Munich Gmbh Antibody constructs for cldn18.2 and cd3
UY38393A (es) 2018-09-28 2020-03-31 Amgen Inc Anticuerpos contra bcma soluble
MA53822A (fr) 2018-10-03 2021-08-11 Xencor Inc Protéines de fusion fc hétérodimères d'il -12
NL2021789B1 (en) 2018-10-10 2020-05-14 Academisch Ziekenhuis Leiden Binding proteins specific for HA-1H and uses thereof
PE20211867A1 (es) 2018-11-01 2021-09-21 Shandong New Time Pharmaceutical Co Ltd Anticuerpos biespecificos y su uso
AU2019383976B2 (en) 2018-11-19 2025-07-03 Bt Bidco, Inc. Methods and devices for treating a disease with biotherapeutics
SG11202109406TA (en) 2019-03-01 2021-09-29 Xencor Inc Heterodimeric antibodies that bind enpp3 and cd3
SG11202111027WA (en) 2019-04-05 2021-11-29 Teneobio Inc Heavy chain antibodies binding to psma
EP3984554A4 (en) 2019-06-11 2023-11-08 ONO Pharmaceutical Co., Ltd. IMMUNOSUPPRESSION AGENT
TW202504931A (zh) 2019-06-14 2025-02-01 美商泰尼歐生物公司 與ｃｄ２２及ｃｄ３結合之多特異性重鏈抗體
MX2022001882A (es) 2019-08-12 2022-05-30 Aptevo Res & Development Llc Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
CR20220076A (es) 2019-08-30 2022-06-24 Agenus Inc Anticuerpos anti-cd96 y sus métodos de uso
FI3819007T3 (fi) 2019-11-11 2024-09-25 Amgen Res Munich Gmbh Annosteluohjelma anti-bcma-aineille
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
UY39135A (es) 2020-03-26 2021-10-29 Univ Vanderbilt ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
CN115715220A (zh) 2020-04-29 2023-02-24 特尼奥生物股份有限公司 具有经修饰重链恒定区的多特异性重链抗体
JP2023528223A (ja) 2020-05-13 2023-07-04 ディスク・メディシン・インコーポレイテッド 骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US20210355196A1 (en) 2020-05-17 2021-11-18 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of selecting and using the same
EP4153633A1 (en) 2020-05-19 2023-03-29 Amgen Inc. Mageb2 binding constructs
JP2023536904A (ja) 2020-08-06 2023-08-30 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体が媒介する疾患を有する対象における炎症性サイトカインおよび疲労
IL300257A (en) 2020-08-10 2023-03-01 Astrazeneca Uk Ltd SARS-COV-2 antibodies for the treatment and prevention of COVID-19
MX2023001962A (es) 2020-08-19 2023-04-26 Xencor Inc Composiciones anti-cd28.
NL2026614B1 (en) 2020-10-02 2022-06-03 Academisch Ziekenhuis Leiden T cell receptors directed against bob1 and uses thereof
TW202233679A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 選擇性地與cldn6和cd3結合的多肽構建體
AR124017A1 (es) 2020-11-06 2023-02-01 Amgen Res Munich Gmbh Polipéptidos con perfil de recorte potenciado
TW202233682A (zh) 2020-11-10 2022-09-01 美商安進公司 用於投與ＢＣＭＡｘＣＤ３結合分子之方法
EP4255574A1 (en) 2020-12-01 2023-10-11 Aptevo Research and Development LLC Heterodimeric psma and cd3-binding bispecific antibodies
JP2024503609A (ja) 2020-12-31 2024-01-26 ダイン セラピューティクス，インコーポレーテッド 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
TW202304508A (zh) 2021-03-31 2023-02-01 美商百歐維拉提夫美國公司 減少冷凝集素疾病患者之手術相關溶血
JP2024522213A (ja) 2021-06-14 2024-06-11 アルジェニクス ビーブイ 抗ｉｌ－９抗体及びその使用方法
CA3232806A1 (en) 2021-09-30 2023-04-06 Seagen Inc. B7-h4 antibody-drug conjugates for the treatment of cancer
TW202342095A (zh) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９之組成物
EP4433160A1 (en) 2021-11-17 2024-09-25 Disc Medicine, Inc. Methods for treating anemia of kidney disease
NL2030990B1 (en) 2022-02-17 2023-09-01 Academisch Ziekenhuis Leiden T cell receptors directed against jchain and uses thereof
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
NL2031118B1 (en) 2022-03-01 2023-09-07 Academisch Ziekenhuis Leiden T cell receptors directed against transcription factor wt1 and uses thereof
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
EP4514842A1 (en) 2022-04-29 2025-03-05 AstraZeneca UK Limited Sars-cov-2 antibodies and methods of using the same
JP2025516465A (ja) 2022-05-13 2025-05-30 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク 血液悪性腫瘍の治療
NL2032130B1 (en) 2022-06-10 2023-12-18 Academisch Ziekenhuis Leiden T cell receptors directed against melanoma-associated antigen and uses thereof
CN119698296A (zh) 2022-06-15 2025-03-25 美国比奥维拉迪维股份有限公司 抗补体c1s抗体配制品
IL317947A (en) 2022-06-24 2025-02-01 Bioverativ Usa Inc Complementary disease treatment methods
NL2033510B1 (en) 2022-11-11 2024-05-28 Academisch Ziekenhuis Leiden T cell receptors directed against cancer-associated antigens and uses thereof
WO2024150074A2 (en) 2023-01-13 2024-07-18 Takeda Pharmaceutical Company Limited Coronavirus antibodies and therapeutic uses thereof
WO2024182714A1 (en) 2023-03-02 2024-09-06 Alloy Therapeutics, Inc. Anti-cd22 antibodies and uses thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
AU2024240129A1 (en) 2023-03-17 2025-10-09 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
NL2034657B1 (en) 2023-04-21 2024-10-28 Academisch Ziekenhuis Leiden RCN1-derived TEIPP neoantigens and uses thereof
NL2034658B1 (en) 2023-04-21 2024-10-28 Academisch Ziekenhuis Leiden TIMP3-derived TEIPP neoantigens and uses thereof
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
TW202517301A (zh) 2023-10-06 2025-05-01 美商思進公司 用ｂ７－ｈ４抗體－藥物結合物治療晚期實體腫瘤之方法
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
NL2036854B1 (en) 2024-01-22 2025-08-01 Academisch Ziekenhuis Leiden Haematopoietic-restricted Minor Histocompatibility Antigens and uses thereof
NL2036853B1 (en) 2024-01-22 2025-08-01 Academisch Ziekenhuis Leiden Haematopoietic-restricted minor histocompatibility antigens and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
DE68909441T2 (de) * 1988-02-12 1994-02-10 British Tech Group Modifizierte Antikörper.
FI105320B (fi) * 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
ATE159982T1 (de) * 1988-09-15 1997-11-15 Univ Columbia Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung
GB8905669D0 (en) * 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991001752A1 (en) * 1989-07-27 1991-02-21 Fred Hutchinson Cancer Research Center Immunosuppressive monoclonal antibodies, hybridomas and methods of transplantation
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JP2711163B2 (ja) * 1990-01-12 1998-02-10 新日本製鐵株式会社 耐ｃｏ▲下２▼腐食性の優れた高耐食性低合金ラインパイプ用鋼の製造法
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US5968509A (en) * 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
WO1992009967A1 (en) * 1990-11-27 1992-06-11 Paraspectives, Inc. A system for imaging objects in alternative geometries
WO1992022653A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
AU2004263538B2 (en) * 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells

Also Published As

Publication number Publication date
US20060165691A1 (en) 2006-07-27
US20070154477A1 (en) 2007-07-05
AU2766892A (en) 1993-10-21
CA2109815C (en) 2003-02-04
JP4113467B2 (ja) 2008-07-09
ATE155818T1 (de) 1997-08-15
US20060165692A1 (en) 2006-07-27
EP0586617B1 (en) 1997-07-23
DE69221147T2 (de) 1998-01-15
JP2004000249A (ja) 2004-01-08
US20060165693A1 (en) 2006-07-27
AU671085B2 (en) 1996-08-15
US20040202657A1 (en) 2004-10-14
GR3024489T3 (OSRAM) 1997-11-28
DE69221147D1 (de) 1997-09-04
US6706265B1 (en) 2004-03-16
GB9206422D0 (en) 1992-05-06
US20070134241A1 (en) 2007-06-14
JPH07500017A (ja) 1995-01-05
US20070178092A1 (en) 2007-08-02
JP4113890B2 (ja) 2008-07-09
CA2109815A1 (en) 1993-09-30
US5585097A (en) 1996-12-17
KR100238497B1 (ko) 2000-01-15
US20060088526A1 (en) 2006-04-27
JP4065554B2 (ja) 2008-03-26
EP0586617A1 (en) 1994-03-16
JP2006089501A (ja) 2006-04-06
US20060269547A1 (en) 2006-11-30
WO1993019196A1 (en) 1993-09-30

Similar Documents

Publication Publication Date Title
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
FI961285A0 (fi) CD40:n vasta-aineita
EP1266965A3 (en) Recombinant antibodies for human therapy
EP0812333A4 (en) BISPECIFIC ANTIBODIES EFFECTIVE IN THE TREATMENT OF B-CELL AND LINEAR MALIGNANT LYMPHOMAS
ATE248605T1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
AU1518795A (en) Immunoassays for prostate specific antigen
CA2118010A1 (en) Antibodies specific for carcinoma-associated antigens
MY104946A (en) Antigen antibody conjugate.
WO1990015076A3 (en) MONOCLONAL ANTIBODIES AGAINST LEUKOCYTE ADHESION RECEPTOR β-CHAIN, METHODS OF PRODUCING THESE ANTIBODIES AND USE THEREFORE
AU1868695A (en) Immuno-stimulatory monoclonal antibodies
GB2128630A (en) Method of affinity purification employing monoclonal antibodies
GB2185266B (en) Monoclonal antibodies cross-reactive and cross-protective against p. aeruginosa serotypes
ATE87368T1 (de) Monoklonale antikoerper gegen nicht reduzierte, nicht enzymatisch glykolysierte proteine.
FI945865A7 (fi) Glykoprofeiini P:lle kohdistettuja monoklonaalisia vasta-aineita
NZ305083A (en) Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
GB8910263D0 (en) Monoclonal antibodies specific for an immunoglobulin isotype
AU2707992A (en) Monoclonal antibodies to hepatitis c virus
AU567681B2 (en) Immunoassay involving monoclonal igm antibody
AU1423892A (en) Monoclonal antibodies directed towards mycobacterial antigens
EP0194158A3 (en) Anti-nicotine and anti-cotinine antibodies (monoclonal and other), and their uses in nicotine and cotinine assays
AU1626492A (en) Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof
KR890015753A (ko) 항-인간 암 단백질 복합체, 그의 제조방법 및 용도
EP0581108A3 (en) Bispecific antibody reacting with the sialyl-Lea antigen and with CD3.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 586617

Country of ref document: ES